Cell Signaling Technology

Product Pathways - Tyrosine Kinase / Adaptors

Phospho-FLT3 (Tyr589/591) (30D4) Rabbit mAb #3464

Applications Reactivity Sensitivity MW (kDa) Isotype
W H M Endogenous 160 Rabbit IgG

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Phospho-FLT3 (Tyr589/591) (30D4) Rabbit mAb detects endogenous levels of FLT3 protein only when phosphorylated at tyrosine 589/591. The antibody does not cross-react with other phosphorylated tyrosine kinases. (US Patent No. 7,183,385 and foreign equivalents assigned to Cell Signaling Technology, Inc.)

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to the sequences surrounding Tyr589/591 of human FLT3.

Western Blotting

Western Blotting

Western blot analysis of extracts from cells expressing various activated tyrosine kinase proteins, using Phospho-FLT3 (Tyr589/591) (30D4) Rabbit mAb (upper) or Phospho-Tyrosine mAb (P-Tyr-100) #9411 (lower). Phospho-FLT3 (Tyr589/591) (30D4) Rabbit mAb specifically recognizes the activated FLT3 but not non-phosphorylated FLT3 protein.

Background

FMS-related tyrosine kinase 3 (FLT3, also called Flk2), is a member of the type III receptor tyrosine kinase family, which includes c-Kit, PDGFR and M-CSF receptors. FLT3 is expressed on early hematopoietic progenitor cells and supports growth and differentiation within the hematopoietic system (1,2). FLT3 is activated after binding with its ligand FL, which results in a cascade of tyrosine autophosphorylation and tyrosine phosphorylation of downstream targets (3). The p85 subunit of PI3 kinase, SHP2, GRB2 and Shc are associated with FLT3 after FL stimulation (4-6). Tyr589/591 is located in the juxtamembrane region of FLT3 and may play an important role in regulation of FLT3 tyrosine kinase activity. Somatic mutations of FLT3 consisting of internal tandem duplications (ITDs) occur in 20% of patients with acute myeloid leukemia (7).

  1. Shurin, M.R. et al. (1998) Cytokine Growth Factor Rev. 9, 37-48.
  2. Naoe, T. et al. (2001) Cancer Chemother. Pharmacol. 48 Suppl1, S27-S30.
  3. Namikawa, R. et al. (1996) Stem Cells 14, 388-395.
  4. Beslu, N. et al. (1996) J. Biol. Chem. 271, 20075-20081.
  5. Zhang, S. and Broxmeyer, H.E. (2000) Biochem. Biophys. Res. Commun. 277, 195-199.
  6. Zhang, S. et al. (1999) J. Leukoc. Biol. 65, 372-380.
  7. Mizuki, M. et al. (2000) Blood 96, 3907-3914.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product and (and certain uses thereof) are covered by US Patent No. 7183385 and foreign equivalents assigned to Cell Signaling Technology, Inc. Rabbit Monoclonal Produced Using Epitomics® Technology, U.S. Patent No. 5,675,063.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products